NYSE:PBH - Prestige Consumer Healthcare Stock Price, News, & Analysis

Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."

Prestige Consumer Healthcare Inc (NYSE:PBH) announced its earnings results on Thursday, November, 1st. The company reported $0.65 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.63 by $0.02. The business earned $239.36 million during the quarter, compared to analysts' expectations of $236.28 million. Prestige Consumer Healthcare had a net margin of 33.38% and a return on equity of 11.82%. The firm's revenue was down 7.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.61 earnings per share. View Prestige Consumer Healthcare's Earnings History.

Prestige Consumer Healthcare is scheduled to release their next quarterly earnings announcement on Thursday, February 7th 2019. View Earnings Estimates for Prestige Consumer Healthcare.

Prestige Consumer Healthcare updated its FY19 earnings guidance on Thursday, November, 1st. The company provided EPS guidance of $2.84-2.92 for the period, compared to the Thomson Reuters consensus estimate of $2.86. The company issued revenue guidance of $985-995 million, compared to the consensus revenue estimate of $986.48 million.

3 analysts have issued twelve-month price objectives for Prestige Consumer Healthcare's shares. Their predictions range from $38.00 to $43.00. On average, they anticipate Prestige Consumer Healthcare's share price to reach $39.6667 in the next twelve months. This suggests a possible upside of 16.2% from the stock's current price. View Analyst Price Targets for Prestige Consumer Healthcare.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Prestige Consumer Healthcare.

Media stories about PBH stock have been trending very positive this week, InfoTrie reports. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Prestige Consumer Healthcare earned a news sentiment score of 3.9 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future.

Some companies that are related to Prestige Consumer Healthcare include Ionis Pharmaceuticals (IONS), Nektar Therapeutics (NKTR), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), Alkermes (ALKS), Catalent (CTLT), Amneal Pharmaceuticals (AMRX), GALAPAGOS NV/S (GLPG), SAGE Therapeutics (SAGE), United Therapeutics (UTHR), HUTCHISON CHINA/S (HCM), Loxo Oncology (LOXO), TESARO (TSRO), Taro Pharmaceutical Industries (TARO) and GW Pharmaceuticals PLC- (GWPH).

Prestige Consumer Healthcare's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.00%), FMR LLC (11.30%), Vanguard Group Inc. (9.09%), Dimensional Fund Advisors LP (7.02%), JPMorgan Chase & Co. (5.86%) and Wells Fargo & Company MN (4.23%). Company insiders that own Prestige Consumer Healthcare stock include Gary E Costley, Jean A Boyko, Natale S Ricciardi, Ronald M Lombardi, Timothy Connors and William P'pool. View Institutional Ownership Trends for Prestige Consumer Healthcare.

PBH stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., BlackRock Inc., Fisher Asset Management LLC, Dupont Capital Management Corp, Allianz Asset Management GmbH, Fuller & Thaler Asset Management Inc., AQR Capital Management LLC and FMR LLC. Company insiders that have sold Prestige Consumer Healthcare company stock in the last year include Jean A Boyko and Timothy Connors. View Insider Buying and Selling for Prestige Consumer Healthcare.

PBH stock was bought by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., Dimensional Fund Advisors LP, Massachusetts Financial Services Co. MA, Macquarie Group Ltd., JPMorgan Chase & Co., Acadian Asset Management LLC, Man Group plc and Rice Hall James & Associates LLC. Company insiders that have bought Prestige Consumer Healthcare stock in the last two years include Gary E Costley, Natale S Ricciardi, Ronald M Lombardi and William P'pool. View Insider Buying and Selling for Prestige Consumer Healthcare.

Shares of PBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PBH stock can currently be purchased for approximately $34.15.

Prestige Consumer Healthcare has a market capitalization of $1.86 billion and generates $1.04 billion in revenue each year. The company earns $339.57 million in net income (profit) each year or $2.58 on an earnings per share basis. Prestige Consumer Healthcare employs 530 workers across the globe.

The official website for Prestige Consumer Healthcare is http://www.prestigebrands.com.

Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD, TARRYTOWN NY, 10591. The company can be reached via phone at 914-524-6800 or via email at [email protected]